Can J Cardiol 2017 Dec 15. Epub 2017 Dec 15.
Department of Medicine, Department of Physiology, Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada; Division of Endocrinology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address:
Despite the effectiveness of low-density lipoprotein (LDL)-lowering strategies for the treatment of diabetic dyslipidemia, significant residual risk of atherosclerotic cardiovascular disease remains. Residual risk might in part be explained by lipid abnormalities that go beyond LDL cholesterol elevation, collectively termed the "atherogenic dyslipidemia complex (ADC)," consisting of hypertriglyceridemia, elevated small dense LDL particles, reduced high-density lipoprotein cholesterol, and high-density lipoprotein particle numbers, increased remnant lipoproteins, and postprandial hyperlipidemia. In this review, we briefly discuss the pathophysiology of the typical dyslipidemia that occurs in insulin-resistant states including obesity, the metabolic syndrome, and type 2 diabetes. Read More